CAR-T Cell Therapies Market (3rd Edition) by Target Indications by Roots Analysis

Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status

Roots Analysis is pleased to announce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030”

The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
 A detailed assessment of the current market landscape of drug developers engaged in the development of CAR-T cell therapies.
 Detailed profiles of marketed and mid-to late stage clinical products (shortlisted on the basis of the stage of development).
 An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy.
 An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
 An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019.

Leave a Reply